Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide
Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide(429 views) Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
References: Baldelli, R., Ferretti, E., Jaffrain-Rea, M.L., Iacobellis, G., Minniti, G., Caracciolo, B., Moroni, C., Tamburrano, G., Cardiac effects of lanreotide, a slow release somatostatin analog, in acromegalic patients (1999) Journal of Clinical Endocrinology and Metabolism, 84, pp. 575-53
Bates, A.S., Van't Hoff, W., Jones, J.M., Clayton, R.N., An audit of outcome of treatment in acromegaly (1993) Quarterly Journal of Medicine, 86, pp. 293-299
Bengtsson, B., Eden, S., Ernest, I., Oden, A., Sjogren, B., Epidemiology and long term survival in acromegaly (1988) Acta Medica Scandinavica, 223, pp. 327-335
Colao, A., Baldelli, R., Marzullo, P., Ferretti, E., Ferone, D., Gargiulo, P., Petretta, M., Liuzzi, A., Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy (2000) Journal of Clinical Endocrinology and Metabolism, 85, pp. 193-199
Colao, A., Cuocolo, A., Marzullo, P., Nicolai, E., Ferone, D., Della Morte, A.M., Pivonello, R., Lombardi, G., Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance (2001) Journal of Clinical Endocrinology Metabolism, 86, pp. 1551-1557
Colao, A., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Di Sarno, A., Longobardi, S., Lombardi, G., Prediction of efficacy of octreotide therapy in patients with acromegaly (1996) Journal of Clinical Endocrinology Metabolism, 81, pp. 2356-2362
Colao, A., Lombardi, G., Growth hormone and prolactin excess (1998) Lancet, 352, pp. 1455-1461
Colao, A., Marzullo, P., Di Somma, C., Lombardi, G., Growth hormone and the heart (2001) Clinical Endocrinology, 54, pp. 137-154
Colao, A., Merola, B., Ferone, D., Lombardi, G., Extensive personal experience: Acromegaly (1997) Journal of Clinical Endocrinology and Metabolism, 82, pp. 2777-2781
Colao, A., Spinelli, L., Cuocolo, A., Spiezia, S., Pivonello, R., Di Somma, C., Bonaduce, D., Lombardi, G., Cardiovascular consequences of early-onset growth hormone excess (2002) Journal of Clinical Endocrinology Metabolism, 87, pp. 3097-3104
Fazio, S., Cittadini, A., Biondi, B., Palmieri, E.A., Riccio, G., Bonè, F., Oliviero, U., Saccà, L., Cardiovascular effects of short-term growth hormone hypersecretion (2000) Journal of Clinical Endocrinology and Metabolism, 85, pp. 179-182
Giustina, A., Barkan, A., Casanueva, F.F., Cavagnini, F., Frohman, L., Ho, K., Veldhuis, J., Melmed, S., Criteria for cure of acromegaly: A consensus statement (2000) Journal of Clinical Endocrinology and Metabolism, 85, pp. 526-529
Hayward, R.P., Emanuel, R.W., Nabarro, J.D.N., Acromegalic heart disease: Influence of treatment of the acromegaly on the heart (1987) Quarterly Journal of Medicine, 62, pp. 41-58
Hejtmancik, M.R., Bradfield, J.Y., Herrmann, G.R., Acromegaly and the heart: A clinical and pathologic study (1951) Annals of Internal Medicine, 34, pp. 1445-1456
Hradec, J., Kral, J., Janota, T., Krsek, M., Hana, V., Marek, J., Malik, M., Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog) (1999) American Journal of Cardiology, 83, pp. 1506-1509
Lancranjan, I., Atkinson, A.B., Results of a European multicentre study with sandostatin LAR in acromegalic patients (1999) Pituitary, 1, pp. 105-114
Lie, J.T., Grossman, S.J., Pathology of the heart in acromegaly: Anatomic findings in 27 autopsied patients (1980) American Heart Journal, 100, pp. 41-52
Lim, M.J., Barkan, A.L., Buda, A.J., Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion (1992) Annals of Internal Medicine, 117, pp. 719-726
López-Velasco, R., Escobar-Morreale, H.F., Vega, B., Villa, E., Sancho, J.M., Moya-Mur, J.L., Garcia-Robles, R., Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension (1997) Journal of Clinical Endocrinology Metabolism, 82, pp. 1047-1053
McGuffin W.L., Jr., Sherman, B.M., Roth, J., Gorden, P., Kahn, C.R., Roberts, W.C., Frommer, P.L., Acromegaly and cardiovascular disorders: A prospective study (1974) Annals of Internal Medicine, 81, pp. 11-18
Merola, B., Cittadini, A., Colao, A., Ferone, D., Fazio, S., Sabatini, D., Biondi, B., Lombardi, G., Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly (1993) Journal of Clinical Endocrinology and Metabolism, 77, pp. 790-793
Minniti, G., Jaffrain-Rea, M.L., Moroni, C., Baldelli, R., Ferretti, E., Cassone, R., Gulino, A., Tamburrano, G., Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics (1998) Clinical Endocrinology, 49, pp. 101-106
Morvan, D., Komajda, M., Grimaldi, A., Turpin, G., Grosgogeat, Y., Cardiac hypertrophy and function in asymptomatic acromegaly (1991) European Heart Journal, 12, pp. 666-672
Orme, S.M., McNally, R.J., Cartwright, R.A., Belchetz, P.E., Mortality and cancer incidence in acromegaly: A retrospective cohort study (1998) Journal of Clinical Endocrinology and Metabolism, 83, pp. 2730-2734. , United Kingdom Acromegaly Study Group
Pereira, J., Rodriguez-Puras, M.J., Leal-Cerro, A., Martinez, A., Garcial-Luna, P.P., Gavilan, I., Pumar, A., Astorga, R., Acromegalic cardiopathy improves after treatment with increasing doses of octreotide (1991) Journal of Endocrinological Investigation, 14, pp. 17-23
Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J., Ibbertson, H.K., Determinants of clinical outcome and survival in acromegaly (1994) Clinical Endocrinology, 41, pp. 95-102
Sahn, D.J., De Maria, A., Kissio, J., Weyman, A., The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiography measurements (1978) Circulation, 58, pp. 1072-1083
Savage, D.D., Henry, W.L., Eastman, R.C., Borer, J.S., Gorden, P., Echocardiographic assessment of cardiac anatomy and function in patients (1979) American Journal of Medicine, 67, pp. 823-829
Smallridge, R.C., Rajfer, S., Davia, J., Schaaf, M., Acromegaly and the heart. An echocardiographic study (1979) American Journal of Medicine, 66, pp. 22-27
Thuesen, L., Christensen, S.E., Weeke, J., Orskov, H., Henningsen, P., A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients? (1988) Acta Medica Scandinavica, 223, pp. 337-343
Tokgözoglu, S.L., Erbas, T., Aytemir, K., Akalin, S., Kes, S., Oram, E., Effects of octreotide on left ventricular mass in acromegaly (1994) American Journal of Cardiology, 74, pp. 1072-1074
Wright, A.D., Hill, D.M., Lowy, C., Fraser, T.R., Mortality in acromegaly (1970) Quarterly Journal of Medicine, 39, pp. 1-16
Bates, A. S., Van't Hoff, W., Jones, J. M., Clayton, R. N., An audit of outcome of treatment in acromegaly (1993) Quarterly Journal of Medicine, 86, pp. 293-299
Hayward, R. P., Emanuel, R. W., Nabarro, J. D. N., Acromegalic heart disease: Influence of treatment of the acromegaly on the heart (1987) Quarterly Journal of Medicine, 62, pp. 41-58
Hejtmancik, M. R., Bradfield, J. Y., Herrmann, G. R., Acromegaly and the heart: A clinical and pathologic study (1951) Annals of Internal Medicine, 34, pp. 1445-1456
Lie, J. T., Grossman, S. J., Pathology of the heart in acromegaly: Anatomic findings in 27 autopsied patients (1980) American Heart Journal, 100, pp. 41-52
Lim, M. J., Barkan, A. L., Buda, A. J., Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion (1992) Annals of Internal Medicine, 117, pp. 719-726
L pez-Velasco, R., Escobar-Morreale, H. F., Vega, B., Villa, E., Sancho, J. M., Moya-Mur, J. L., Garcia-Robles, R., Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension (1997) Journal of Clinical Endocrinology Metabolism, 82, pp. 1047-1053
McGuffin W. L., Jr., Sherman, B. M., Roth, J., Gorden, P., Kahn, C. R., Roberts, W. C., Frommer, P. L., Acromegaly and cardiovascular disorders: A prospective study (1974) Annals of Internal Medicine, 81, pp. 11-18
Orme, S. M., McNally, R. J., Cartwright, R. A., Belchetz, P. E., Mortality and cancer incidence in acromegaly: A retrospective cohort study (1998) Journal of Clinical Endocrinology and Metabolism, 83, pp. 2730-2734. , United Kingdom Acromegaly Study Group
Sahn, D. J., De Maria, A., Kissio, J., Weyman, A., The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiography measurements (1978) Circulation, 58, pp. 1072-1083
Savage, D. D., Henry, W. L., Eastman, R. C., Borer, J. S., Gorden, P., Echocardiographic assessment of cardiac anatomy and function in patients (1979) American Journal of Medicine, 67, pp. 823-829
Smallridge, R. C., Rajfer, S., Davia, J., Schaaf, M., Acromegaly and the heart. An echocardiographic study (1979) American Journal of Medicine, 66, pp. 22-27
Tokg zoglu, S. L., Erbas, T., Aytemir, K., Akalin, S., Kes, S., Oram, E., Effects of octreotide on left ventricular mass in acromegaly (1994) American Journal of Cardiology, 74, pp. 1072-1074
Wright, A. D., Hill, D. M., Lowy, C., Fraser, T. R., Mortality in acromegaly (1970) Quarterly Journal of Medicine, 39, pp. 1-16
Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide
BACKGROUND: Cardiovascular disease is the most frequent cause of death of patients with acromegaly. AIM To investigate whether young patients with a presumed short disease duration are more likely to reverse the acromegalic cardiomyopathy than older patients with longer disease duration. DESIGN: An open prospective design. PATIENTS: Ten young (aged < 40 years), and 12 middle-aged (41-59 years) patients with active acromegaly well controlled after 12 months of treatment with the depot formulation of octreotide (OCT-LAR); 22 sex- and age-matched healthy subjects as controls. METHODS: Left ventricular (LV) mass (LVM) by echocardiography and performance by equilibrium radionuclide angiography were measured before and after 12 months of OCT-LAR treatment. RESULTS: At study entry, none of the controls and 14 patients (63.4%) of whom six were young (χ2 = 17.7; P < 0.0001) had LV hypertrophy (LVH); none of the controls and four patients of whom one was young had insufficient LV ejection fraction (LVEF) at rest (< 50%); one control and 13 patients (59.1%) of whom five were young (χ2= 12.7; P < 0.0001) had inadequate LVEF at peak exercise (ΔLVEF; < 5% increase of baseline). After 12 months, no change in haemodynamic and diastolic parameters was observed in both groups, except for a significant decrease in heart rate at peak exercise in young patients (P < 0.0001). The LVM index decreased significantly in both young (124.4 ± 5.8 vs. 103.4 ± 3.9 g/m2; P = 0.01) and middle-aged patients (140.9 ± 7.9 vs. 117.8 ± 6.6 g/m2; P= 0.03). LVH disappeared in 10 of 14 patients (71.4%): all six young and four of eight middle-aged patients (50%). LVEF at rest and at peak exercise increased significantly in both groups but ΔLVEF increased significantly only in young patients (1.5 ± 2.9 vs. 13.7 ± 5.2%, P= 0.04); it normalized in nine of 13 patients (69.2%), four of five young (80%) and four of eight middle-aged patients (50%). Exercise capacity (82.5 ± 5.3 vs. 110.0 ± 5.5 W, P= 0.005) and duration (7.3 ± 0.3 vs. 9.9 ± 0.4 min, P = 0.0003) also increased only in young patients. CONCLUSIONS: The acromegalic cardiomyopathy is reversed in most young patients with short disease duration and achieving disease control after OCT-LAR treatment for 12 months, indicating that early diagnosis and effective treatment are essential.
Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide
Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide